Valeo Pharma EBIT

Valeo Pharma (VPHIF) currently reports a EBIT of $-19M as of July 2024. That compares with $-17M in the prior-year period — down 10.6% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Valeo Pharma's EBIT history and peer comparisons.

Valeo Pharma's EBIT decreased from $-17M to $-19M — a 10.6% year-over-year decrease (period ending July 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Valeo Pharma's EBIT of $-19M is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Valeo Pharma reported $-19M in EBIT as of July 2024. That compares with $-17M in the prior-year period — down 10.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-19M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Valeo Pharma, and consider following VPHIF for alerts when major investors trade the stock.